ANRIL promotes the proliferation and migration of prostate cancer cells through the regulation let-7a/TGF-β1/Smad signaling pathway that regulates the proliferation, migration, and epithelial-mesenchymal transition (EMT) of prostate cancer [126]. Here, CDKN2B-AS1 is linked to prostate cancer.